Professor Dame Linda Partridge FRS FRSE FMedSci CBE DBE
Linda Partridge works on the biology of ageing. Her research is directed to understanding the mechanisms by which the healthy period of life can be extended in laboratory model organisms and in humans. She has focussed on the role of the nutrient-sensing signalling network and of diet. Her primary current interest is in the potential to repurpose drugs for geroprotection.
She is the recipient of numerous awards. She is a Fellow of the Royal Society, the Academy of Medical Sciences and a foreign member of the American Academy of Arts and Sciences and the German Academy of Sciences Leopoldina. She is the emeritus founding director of the Max Planck Institute for Biology of Ageing in Cologne, Germany.

Magdalena Zernicka-Goetz is the Bren Professor of Biology and Biological Engineering at the California Institute of Technology. A leading developmental biologist, she earned her Ph.D. in Mammalian Embryology from the University of Warsaw and completed postdoctoral training in Embryonic Stem Cell Biology at the University of Cambridge with Nobel Laureates Martin Evans and John Gurdon. Her research has redefined the understanding of early mammalian development, revealing cellular heterogeneity in the early embryo, the role of epigenetic mechanisms in cell fate determination, and the processes by which aneuploid cells are selectively eliminated. Her lab was the first to establish a culture system that supports human embryo development beyond implantation up to the legal 14-day limit, and pioneered development of stem cell-based embryo models. A recipient of continuous funding from the Wellcome Trust, ERC, NIH, and philanthropic foundations, she has published over 180 scientific papers and co-authored The Dance of Life: Symmetry, Cells, and How We Become Human. She was awarded the 2023 Ogawa-Yamanaka Stem Cell Prize, and her numerous honors include membership in the European Molecular Biology Organization, Foreign Membership in the Polish Academy of Sciences and the Polish Academy of Arts and Sciences, and a Fellowship of the British Academy of Medical Sciences.

Eiji Hara received his Ph.D. from the Tokyo University of Science in 1993 and carried out postdoctoral research in Judith Campisi’s lab at UC Berkeley and in Gordon Peters’s lab at the Imperial Cancer Research Fund in London, before becoming Group Leader at the Paterson Institute for Cancer Research (now the Cancer Research UK Manchester Institute) in 1998. He returned to Japan in 2003 as a Professor at the University of Tokushima, then moved to the Japanese Foundation for Cancer Research in 2008 and the University of Osaka in 2015, maintaining a focus on cellular senescence throughout his research career.

Dr. Jones received her BS degree from Washington and Lee University in Lexington, Virginia. She did her undergraduate thesis research developing novel mutagenesis protocols for Sindbis virus under the guidance of Dr. Darcy Russell and in the process, developed a lifelong love of viruses and virology.
She then received her PhD degree in Microbiology and Molecular Genetics from Harvard University, where she performed her thesis work in the Department of Pathology with Dr. Karl Münger. Her work on DNA tumor viruses introduced her to cancer cell biology and founded her long-term research goals of characterizing the mechanisms that influence the cell fate decision between proliferation (cell division) and differentiation (specialization of function).
To complement her background in biochemistry and expertise in mammalian cell culture, Dr. Jones then went to the University of Sheffield and Stanford University School of Medicine to learn genetics and developmental biology in the laboratories of Prof. Philip Ingham and Dr. Margaret Fuller, respectively. It was during this time that she began to apply what she had learned about tumor initiation and progression to the study of stem cells.
After her postdoctoral work, Dr. Jones became an Assistant Professor in the Laboratory of Genetics at the Salk Institute for Biological Studies in San Diego, CA. In 2013, Dr. Jones moved her lab to the University of California- Los Angeles, where she was a Professor in the Department of Molecular, Cell, and Developmental Biology. In 2021, she moved to the University of California- San Francisco to join the Department of Anatomy, with a joint appointment in the Department of Medicine and the Division of Geriatrics.   She currently serves as the Inaugural Director of the Bakar Aging Research Institute and as a member of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research.

I am an Associate Professor at the Mayo Clinic in Rochester in the Department of Hematology and co-Director of the Aging and Cancer Program at the Kogod Aging Center at Mayo Clinic. I am interested in age-related changes in the early stages of carcinogenesis with the aim of early detection. My group investigates hematopoietic stem cell aging and senescence alongside age-associated clonal hematopoiesis on a functional, metabolic, and transcriptional level.
I obtained my Ph.D. from the University of Edinburgh, characterizing one of the first DNA damage-dependent premature ageing mouse models. During my post-doc at the CRUK Cambridge Institute, I revealed previously unanticipated levels of complexity in p53’s response to stress, identifying specific transcriptional patterns in senescence. Seeking a more readily translatable disease model and appreciating the pioneering history of leukemia studies for understanding cancer I joined Prof. Anthony Green’s lab at the University of Cambridge. Ageing is the biggest single cause of cancer, and I therefore combined my expertise in ageing and cancer leading the way in identifying JAK/STAT driven transcriptional clonal hematopoiesis by single cell RNA-seq. For eight years, I held a position as Group Leader/Associate Professor in the School of Cancer Sciences and the Cancer Research UK Scotland Institute, University of Glasgow, U.K. where I developed a framework to estimate the effects of clonal hematopoiesis mutations on adverse outcomes in human aging cohorts.

Prof. Neri obtained PhD in Biotechnology in Siena (Italy) working on embryonic stem cells epigenetics. Then he worked as postdoc between Human Genetics Foundation (HuGeF) in Torino (Italy) and the Radboud University Medical Centre, Nijmegen (Netherlands) where specialized his research on the DNA methylation specific epigenetic mark on stem cell, differentiation and colon cancer. During this period, he characterized new mechanisms of gene transcriptional regulation, developed new epigenomic genome-wide methods and identified the role of the intragenic methylation. In 2015,  Prof. Neri was appointed as Group Leader of the “Epigenetics research group” at the Fritz Lipmann Leibniz Institute on Aging (FLI) in Jena (Germany). His research was supported by the Sofja Kovalevskaja starting grant of the von Humboldt foundation, and it was focused on the aging-dependent epigenetic aberrations occurring in adult stem cells promoting colon cancer. In 2021, Prof. Neri moved his laboratory at the University of Torino, where he is Full Professor of Molecular Biology and is leading the research group of Epigenetics of Aging & Cancer at the Molecular Biotechnology Center (MBC) in Torino. The current research of Prof. Neri focuses on inflammaging, intestinal stem cell aging, epigenetic drifts and how aging functionally impacts on colon cancer initiation.

Ryuichi Nishinakamura graduated from the University of Tokyo School of Medicine and worked as a clinical nephrologist for several years. After receiving his Ph.D., he started working on kidney development at the University of Tokyo. In 2004, he moved to Kumamoto University, where he became a professor at the Institute of Molecular Embryology and Genetics. He also served as the institute's director for four years, until 2020. He pioneered genetic research in developmental nephrology and identified several key genes by generating knockout mice with kidney defects. Based on these findings, he successfully generated two types of kidney organoids (nephron and ureteric bud) from pluripotent stem cells. Recently, he reported on modeling kidney disease from patient-derived iPS cells and generating more complex, branched kidney organoids. His ultimate goal is to create a transplantable kidney.

The Peng Lab is interested in how fibroblasts integrate extracellular cues to modify the tissue niche, with a particular focus on fibroblasts that support tissue-resident stem cells and immune cells. We utilize complex murine genetic models and human specimen to interrogate how fibroblasts maintain organ homeostasis, initiate disease, and drive tissue aging. Tien is a pulmonologist by training and the lab utilizes the lung as a model organ due to its immense cellular diversity and architectural complexity.

Giorgia Quadrato is an Associate Professor at USC’s Department of Stem Cell Biology and Regenerative Medicine. She is also the Director of the USC CIRM ASCEND Shared Resource Laboratory, dedicated to offering organoids and other stem cell-based models, analyses, consultations, and in-depth education and training. Dr. Quadrato’s lab focuses on understanding the cellular and molecular basis of human brain development and disease. By combining the use of emerging models of the human brain with single-cell omics approaches, she is aiming to identify cell type-specific disease mechanisms and, above all, new treatments for human neurodevelopmental disorders. Quadrato received the 2019 Donald E. and Delia B. Baxter Foundation Faculty Scholar Award, the 2020 Edward Mallinckrodt, Jr. Foundation Early Career Faculty Award, and the 2022 Broad Innovation Award. Since 2024, she has been a member of the Scientific Advisory Boards for the Syngap Research Fund (SRF) and Quiver Bioscience.

Peter Rugg-Gunn is a Senior Group Leader at the Babraham Institute in Cambridge. He is also an Affiliate Principal Investigator at the Cambridge Stem Cell Institute and at the Loke Centre for Trophoblast Research, and is the Chief Investigator of the Human Developmental Biology Initiative. Peter obtained a BSc from the University of York, a PhD at the University of Cambridge, and then undertook postdoctoral training at The Hospital for Sick Children, Toronto. In 2011, he received a Wellcome Fellowship that enabled him to establish his research group at the Babraham Institute, where he was awarded tenure in 2017. Peter's research interests centre on understanding how the epigenome is established during human development and how this affects cell fate decisions in human embryos and in stem cell-based embryo models. His group is particularly interested in epigenetic mechanisms that contribute to cellular plasticity and lineage specification. Peter is also the Head of Public Engagement at the Babraham Institute and he has co-led national projects exploring society's views on human embryo research.

James DeGregori is a Professor in the Department of Biochemistry and Molecular Genetics (faculty since 1997) and Deputy Director of the University of Colorado Cancer Center. He has degrees from the University of Texas at Austin (B.A. Microbiology) and the Massachusetts Institute of Technology (PhD Biology), and received postdoctoral training at Duke University. He holds the Courtenay and Lucy Patten Davis Endowed Chair in Lung Cancer Research, and is Editor-in-Chief of the journal Aging And Cancer.
His lab studies the evolution of cancer, in the context of their Adaptive Oncogenesis model, with a focus on how aging, smoking, Down Syndrome, and other insults influence cancer initiation and responses to therapy. In this model, mutations face fitness landscapes that vary with age, genetics, or following carcinogen exposure. These fitness landscapes are highly dependent on the state of the tissue microenvironment in which stem cells reside. The lab has developed this cancer model based on classic evolutionary principles, and substantiated this model by theoretical, experimental and computational studies. Additional studies in the lab seek to identify metabolic and signaling vulnerabilities in cancer, with a focus on acute myeloid leukemias, that can be exploited for the development of more effective therapies.  For all of these studies, they leverage a variety of tools, including computational biology, genomics, metabolomics, cell biology, and biochemistry, leveraging both mouse models and human samples.